MSK scientists find a way to slow T cell exhaustion in cancer immunotherapy

Researchers at Memorial Sloan Kettering Cancer Center identified the signaling molecule MEK as a key driver of T cell exhaustion during immunotherapy. Blocking MEK in animal studies helped T cells stay active longer, and FDA-approved MEK inhibitors could allow rapid testing in humans.

• MEK identified as a key driver of terminal T cell exhaustion
• MEK inhibitors made T cells multiply more while using less energy
• FDA-approved MEK inhibitors allow fast testing in humans
• The approach may not suit all patients: attack may weaken but last longer